Pegapamodutide

Pegapamodutide is a PEGylated analog of amylin designed to achieve long-acting duration suitable for weekly administration. Native amylin and its analog pramlintide require multiple daily injections due to rapid clearance, limiting patient compliance and clinical utility. PEGylation addresses this limitation.

The compound incorporates modifications to prevent the amyloid fibril formation that plagues native amylin, combined with site-specific PEGylation to extend plasma half-life from hours to days. The PEG moiety provides steric shielding against proteolysis and reduces renal clearance.

Amylin receptors in the area postrema and other brain regions mediate satiety signaling complementary to GLP-1 pathways. By providing sustained amylin receptor activation, pegapamodutide aims to achieve durable appetite suppression that enhances the effects of GLP-1 agonist therapy.

Development of pegapamodutide reflects the broader strategy of creating long-acting versions of endogenous satiety signals. Its potential combination with GLP-1 agonists (similar to cagrilintide + semaglutide) could provide multi-pathway appetite control with potentially greater efficacy than single-target approaches.